<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00240682</url>
  </required_header>
  <id_info>
    <org_study_id>2005-001098-82</org_study_id>
    <nct_id>NCT00240682</nct_id>
  </id_info>
  <brief_title>Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR</brief_title>
  <acronym>CTXSCC</acronym>
  <official_title>Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier of Chartres</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital of Chartres- France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier of Chartres</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether cetuximab is effective in the treatment of
      locally advanced or metastatic squamous cell carcinoma of the skin expressing EGFR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with locally advanced or metastatic squamous cell carcinoma (SCC) of the skin are
      often bad responders to conventional chemotherapy included cisplatin.

      The investigation of the EGFR expression may allow identifying new molecular targets for
      novel therapeutic strategies in patients with locally advanced or metastatic SCC of the skin.

      Several publications in the literature for primary lesions and one publication for metastatic
      lesions showed that EGFR was expressed in 80-90% of SCC of the skin. Immunohistochemistry
      studies performed at the Gustave Roussy Institute confirm these data: they found an
      over-expression of EGFR in 90% of patients with metastatic disease. These results are in
      favor of the investigation of cetuximab in patients with locally advanced or metastatic SCC
      of the skin expressing EGFR.

      Cetuximab is a monoclonal antibody targeted against EGFR administered weekly by intravenous
      route; it may be prescribed as out hospital to patients with locally advanced or metastatic
      SCC of the skin expressing EGFR.

      Due to the low occurrence of locally advanced or metastatic SCC of the skin, a multicenter
      trial will be required.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate assessed by CT or MRI</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile.</measure>
    <time_frame>during treatment or within 30 days after the final administration with a cut-off date at week 48.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression.</measure>
    <time_frame>number of days from the start of treatment to the earliest day of progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>from the first infusion until week 48 or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in responder patients at 6 weeks.</measure>
    <time_frame>time to disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Skin Diseases</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <arm_group>
    <arm_group_label>cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.</description>
    <arm_group_label>cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological SCC of the skin expressing (IHC) moderately or highly the EGFR (++ and
             +++, on a semi-quantitative scale).

          -  Locally advanced or metastatic SCC of the skin not suitable for local surgery with
             documented progression.

          -  Presence of at least one measurable target lesion by RECIST criteria.

          -  At least one lesion accessible to biopsies.

          -  ECOG Performance status &lt; 2.

          -  Life expectancy &gt; 3 months.

          -  Age &gt; 18 years.

          -  Normal hematological (Neutrophils &gt; 1.5x109 cells/l, platelets &gt; 100x109 cells/l),
             hepatic (bilirubin &lt; 1.5 times the upper limit of the normal range (ULN); alkaline
             phosphatase and transaminases &lt; 5 x UNL in case of hepatic metastases or &lt; 2.5 x UNL
             in absence of hepatic metastases) and renal (serum creatinine &lt; 150 micromol/L)
             functions.

          -  Written informed consent.

          -  In case of second tumor,excepted carcinoma of the cervix and adequately treated basal
             or squamous cell skin carcinoma, the possibility for including a patient may be
             discussed with the principal investigator.

        Exclusion Criteria:

          -  Prior chemotherapy

          -  Prior radiotherapy &lt; 1 month.

          -  Prior therapy with agent targeting EGFR

          -  Unstable systemic diseases or active uncontrolled infections.

          -  Patients (male and female) not using effective contraception if of reproductive
             potential.

          -  Females pregnant or lactating. Women of child bearing potential must have a negative
             serum or urine pregnancy test prior to start each cycle of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eve Maubec, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Department, Hospital Bichat, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Chartres</name>
      <address>
        <city>Chartres</city>
        <zip>28018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Hôtel Dieu</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaujon's Hospital</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR of Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Tarnier-Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint Louis, Department of P. Morel</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint-Louis, department of L. Dubertret</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eugène Marquis Center</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Maubec E, Duvillard P, Velasco V, Crickx B, Avril MF. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res. 2005 Mar-Apr;25(2B):1205-10.</citation>
    <PMID>15865067</PMID>
  </reference>
  <reference>
    <citation>Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001 Mar 29;344(13):975-83. Review.</citation>
    <PMID>11274625</PMID>
  </reference>
  <reference>
    <citation>Shimizu T, Izumi H, Oga A, Furumoto H, Murakami T, Ofuji R, Muto M, Sasaki K. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology. 2001;202(3):203-6.</citation>
    <PMID>11385224</PMID>
  </reference>
  <reference>
    <citation>Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40.</citation>
    <PMID>10213503</PMID>
  </reference>
  <reference>
    <citation>Barbara A Burtness, Yi Li, William Flood, Bassam I Mattar, Arlene A Forastiere. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head &amp; neck cancer (HNC). Journal of Clinical Oncology,2002 ASCO Annual Meeting Proceedings. Abstract 901.</citation>
  </reference>
  <reference>
    <citation>Nemunaitis JJ, Eiseman I, Cunningham C et al. A phase I trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22: page 243, 2003 (abstr 974).</citation>
  </reference>
  <results_reference>
    <citation>Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentré F, Avril MF. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011 Sep 1;29(25):3419-26. doi: 10.1200/JCO.2010.34.1735. Epub 2011 Aug 1.</citation>
    <PMID>21810686</PMID>
  </results_reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2005</study_first_posted>
  <last_update_submitted>February 18, 2012</last_update_submitted>
  <last_update_submitted_qc>February 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, Squamous Cell</keyword>
  <keyword>Skin</keyword>
  <keyword>cetuximab</keyword>
  <keyword>epidermal growth factor receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

